Recently, two Pin1 inhibitors have been shown to directly bind to the catalytic domain, increase Pin1 degradation, and inhibit Pin1-mediated cell growth in cancer cells (Wei et al., 2015; Campaner et al., 2017; Liao et al., 2017; Zheng et al., 2017; Kozono et al., 2018). The gene discussed is PIN1; the disease is cancer.